Dr. Lisa K. Jennings
is a tenured Professor of Medicine at the University of Tennessee
Health Science Center (UTCHS) in Memphis, Tennessee, USA. She has
secondary appointments at the rank of Professor in the Departments
of Molecular Sciences and Surgery as well as in the Joint Program
of Biomedical Engineering at UTHSC and the University of Memphis.
Dr. Jennings attended graduate school at UTHSC and completed her
Ph.D. thesis research at St. Jude Children's Research Hospital and
the Gladstone Foundation Laboratories in San Francisco. She completed
a post-doctoral fellowship at St. Jude Children's Research Hospital
where she was a Leon Journey Fellow, and was appointed to the faculty
of UTCHS in 1985.
Dr. Jennings is Director of the UTCHS Vascular Biology Center of
and of the TN-AR-MS (TAM) Clinical Research Consortium. Dr. Jennings
has an established research program in the area of platelet biology,
specifically the function of surface membrane receptors and associated
signaling pathways. She has primarily focused on the biology of
the GPIIb-IIIa receptor as well as the tetraspanin CD9. She has
expertise in the study and evaluation of antiplatelet and antithrombin
agents including the design and conduct of the pharmacodynamic assessment
of these agents in pre-clinical studies and in clinical trials.
Clinical trials include IMPACT, IMPACT II, PRIDE, ESPRIT, and PROTECT
trials of eptifibatide (Integrilin), PYRAMID (YM337), ORATOR, TIMI15A
and B (Klerval), PICOLO (clopidogrel) and TAM 1 and TAM 2 trials
(Integrilin vs. Aggrastat or ReoPro).
In addition, her research interests focus on the release of platelet
mediated inflammatory proteins. Other research efforts in the Vascular
Biology Center concentrate on vascular injury response, particularly
signaling pathways associated with smooth muscle migration and proliferation
and restenosis. Dr. Jennings has more than 60 publications in peer-reviewed
journals and 100 abstracts. She has received grant support by the
NIH, the American Heart Association or industry since 1983.